Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A review of the major findings presented at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco
Nevertheless, researchers advise careful kidney monitoring when pairing the medications.
In a recent study of more than 600 HIV-positive adults, 93 percent were cured of hep C.
A recent study of Dutch clinicians found that they generally did a good job of preventing drug-drug interactions.
In a recent small study of HIV-positive men who had recently contracted hepatitis C, Harvoni had a perfect cure rate.
Ending the epidemic is going to require addressing the fact that certain individuals are at high risk of reinfection after a cure.
These include a low CD4 count, having cirrhosis and taking certain hep C drug regimens.
Researchers identified this association after looking at real-world data on a large group of German individuals with HIV and hep C.
Such generic drugs could save nations huge sums in the coming years.
Hepatitis C advocate Peter McLoyd transformed his bad times into good ones.
Highlights from research presented at the 52nd International Liver Congress in Amsterdam
Even those who did not qualify for a treatment shorter than 12 weeks did well on the regimen in a real-world study.
Real-world results of eight weeks of the hepatitis C virus treatment Harvoni (ledipasvir/sofosbuvir) are excellent.
Six weeks of Harvoni cured all acute hep C infections in HIV-positive people with HCV viral loads below 7 million in a recent small trial.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.